Get the app
US › Healthcare

Ardelyx Inc (ARDX)

US · Healthcare · Biotechnology

$2.88-3.68%
Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Revenue
$127.7M
Revenue YoY
+15.7%
Net profit
$-737,000
EPS estimate
$-0.03
Net margin
-0.6%

Key statistics

Market cap
$751.6M
Forward P/E
8.5
P/B
4.58
Book value
$0.65
EPS (TTM)
$-0.23
52-week high
$8.40
52-week low
$2.84
50-day MA
$3.39
200-day MA
$5.27
Beta
0.77

Analyst view

Analysts rate Ardelyx Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $12.80.

Shareholding

Insiders
3.04%
Institutions
72.49%

Largest institutional holders

FundStake
BlackRock Inc9.10%
Rubric Capital Management LP6.28%
Millennium Management LLC5.38%
State Street Corp5.17%
Vanguard Capital Management, LLC4.06%
Delaware Management Holdings Inc3.70%
Vanguard Portfolio Management, LLC3.11%
Geode Capital Management, LLC2.48%

Recent filings & reports

DocumentDate
Quarterly report · Q3 2026
HEADLINE NUMBERS • Third-quarter 2026 total revenue was $127.655 million, up from $110.329 million in the third quarter of 2025. • Nine-month 2026 t
2026-11-03
Results announced · Q4 2026
HEADLINE NUMBERS • Q3 2026 total product revenue was $125.5 million, up 19% from $105.5 million in Q3 2025. • Total revenues, including product supp
2026-11-03
Company announcement · Q3 2026
ARDELYX, INC. - 8-K SUMMARY OTHER NOTABLE POINTS • Chief Commercial Officer Resignation: Eric Foster resigned as Chief Commercial Officer effective
2026-08-17
Quarterly report · Q2 2026
ARDELYX, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Total revenues (6 months ended June 30, 2026): $215.4 million vs. $171.8 million (202
2026-08-06
Results announced · Q3 2026
ARDELYX Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total product revenue: $118.1 million, up 31% year-over-year • IBSRELA Q2 reven
2026-08-06
Current report · Q2 2026
ARDELYX, INC. - FORM 8-K SUMMARY (June 29, 2026) HEADLINE NUMBERS • Company received $50.0 million in debt funding on June 29, 2026 • Loan maturity
2026-07-02
Board / officer change · Q2 2026
ARDELYX, INC. - FORM 8-K SUMMARY (June 16, 2026) HEADLINE NUMBERS • Outstanding shares as of record date (April 22, 2026): 247,029,387 shares of com
2026-06-17
Quarterly report · Q1 2026
ARDELYX, INC. – Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Product sales (net): $93.4 million in Q1 2026 vs. $67.8 million in Q1 2025 (37.7% incre
2026-04-30

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ardelyx Inc — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Data updated 2026-11-07.